Given that CVD and depression are often comorbid, adding a serotonin‐affecting AD to the regimen of those at high risk for thrombosis may bear parallels to dual antiplatelet therapy of aspirin and an ADP inhibitor, which has been found to decrease the risk of secondary cardiovascular events when compared with aspirin alone.34 The gene discussed is WDTC1; the disease is major depressive disorder.